EG624584 Inhibitors
Secretoglobin, family 2B, member 10 (Scgb2b10) is a gene associated with inflammation and immune response, primarily modulating cellular processes through the NF-kappaB signaling pathway. NF-kappaB serves as a central regulator of various immune and inflammatory responses, with Scgb2b10 likely contributing to this intricate regulatory network. The inhibition of Scgb2b10 involves targeting the NF-kappaB pathway directly. Identified inhibitors, such as BAY 11-7082, TPCA-1, and Parthenolide, act by inhibiting key components like IkappaB kinase (IKK), preventing NF-kappaB activation and translocation. This leads to the suppression of Scgb2b10 expression and activity, impacting processes associated with inflammation and immune response. Indirect inhibitors, like Bortezomib and Thalidomide, modulate NF-kappaB activity by affecting the proteasome and downstream signaling events. These inhibitors provide alternative routes to influence Scgb2b10 expression and activity, contributing to the complex regulation of immune and inflammatory processes.
In summary, Scgb2b10 represents a gene intricately linked to the modulation of inflammation and immune responses, with its regulatory mechanisms centered around the NF-kappaB signaling pathway. The identified inhibitors offer insights into potential strategies for manipulating Scgb2b10 expression and activity, providing a foundation for further exploration into the molecular dynamics governing immune and inflammatory processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is a direct inhibitor of Scgb2b10 through inhibition of the NF-kappaB pathway. By blocking the phosphorylation and degradation of IkappaB, it prevents NF-kappaB activation, suppressing Scgb2b10 expression and activity, thereby impacting cellular processes associated with inflammation and immune response. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $130.00 | 12 | |
IKK-2 Inhibitor IV is a direct inhibitor of Scgb2b10 through specific inhibition of IkappaB kinase 2 (IKK2). By targeting IKK2, it disrupts the NF-kappaB signaling pathway, inhibiting the release and translocation of NF-kappaB to the nucleus. This leads to the suppression of Scgb2b10 expression and activity, influencing inflammatory and immune-related cellular processes. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $79.00 $300.00 | 32 | |
Parthenolide is a direct inhibitor of Scgb2b10 through inhibition of NF-kappaB. By preventing the degradation of IkappaB and subsequent nuclear translocation of NF-kappaB, it suppresses Scgb2b10 expression and activity, impacting cellular processes associated with inflammation and immune response. | ||||||
Wedelolactone | 524-12-9 | sc-200648 sc-200648A | 1 mg 5 mg | $108.00 $330.00 | 8 | |
Wedelolactone is a direct inhibitor of Scgb2b10 through inhibition of IkappaB kinase (IKK). By blocking IKK, it interferes with the NF-kappaB pathway, preventing the release and nuclear translocation of NF-kappaB, ultimately suppressing Scgb2b10 expression and activity and influencing processes associated with inflammation and immune response. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
IMD 0354 is a direct inhibitor of Scgb2b10 through selective inhibition of IkappaB kinase (IKK). By specifically targeting IKK, it disrupts the NF-kappaB signaling pathway, leading to the suppression of Scgb2b10 expression and activity, influencing inflammatory and immune-related cellular processes. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $122.00 $516.00 | 55 | |
Bay 11-7085 is a direct inhibitor of Scgb2b10 through inhibition of the NF-kappaB pathway. By blocking the phosphorylation and degradation of IkappaB, it prevents NF-kappaB activation, suppressing Scgb2b10 expression and activity, thereby impacting cellular processes associated with inflammation and immune response. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $210.00 $252.00 $1740.00 $1964.00 | 34 | |
A direct inhibitor of Scgb2b10 through specific inhibition of the translocation of NF-kappaB to the nucleus. By interfering with this crucial step in the NF-kappaB pathway, it suppresses Scgb2b10 expression and activity, influencing cellular processes associated with inflammation and immune response. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $155.00 | 6 | |
Celastrol is a direct inhibitor of Scgb2b10 through modulation of the NF-kappaB pathway. By preventing the phosphorylation and degradation of IkappaB, it inhibits NF-kappaB activation, suppressing Scgb2b10 expression and activity and impacting cellular processes associated with inflammation and immune response. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is an indirect inhibitor of Scgb2b10 through inhibition of the proteasome. By blocking proteasomal degradation, it stabilizes IkappaB, preventing NF-kappaB activation. This results in the suppression of Scgb2b10 expression and activity, influencing processes associated with inflammation and immune response. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide is an indirect inhibitor of Scgb2b10 through modulation of NF-kappaB activity. By suppressing NF-kappaB activation, it leads to the downregulation of Scgb2b10 expression and activity, impacting cellular processes associated with inflammation and immune response. | ||||||